Esperion Therapeutics

ESPRApproved

Esperion Therapeutics is dedicated to improving cardiovascular health by providing convenient, oral therapies that lower LDL-cholesterol (LDL-C) for patients who cannot achieve their treatment goals with statins alone. The company achieved a major milestone with the U.S. FDA approval and commercial launch of NEXLETOL and NEXLIZET in 2020, supported by a robust outcomes trial (CLEAR Outcomes) demonstrating cardiovascular risk reduction. Its strategy focuses on expanding global market access, driving commercial adoption, and leveraging its bempedoic acid platform to potentially address other cardiometabolic conditions.

Market Cap

$654.9M

Employees

200-300

Focus

Biotech

ESPR · Stock Price

USD 2.552.35 (-47.96%)

Historical price data

AI Company Overview

Technology Platform

Oral, once-daily ATP-citrate lyase (ACL) inhibition platform centered on bempedoic acid, a prodrug activated specifically in the liver to lower LDL-cholesterol with a potential muscle-sparing effect.

Pipeline Snapshot

22 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
Bempedoic Acid 180 MG Oral Tablet + Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral T...	Healthy Lactating Women	Approved
Bempedoic Acid / Ezetimibe Oral Tablet + Placebo	Cardiovascular Diseases	Approved
Bempedoic acid 180 mg tablet + Matching placebo tablet	Cardiovascular Diseases	Phase 3
ETC-1002 + Placebo	Hypercholesterolemia	Phase 3
bempedoic acid + placebo	Hypercholesterolemia	Phase 3

FDA Approved Drugs

NEXLIZETNDAFeb 26, 2020

NEXLETOLNDAFeb 21, 2020

Opportunities

The positive cardiovascular outcomes data from the CLEAR Outcomes trial opens a significant opportunity to expand the product label and drive adoption in the large, high-risk statin-intolerant population.

Global market expansion through existing partnerships and potential new geographic territories offers additional revenue growth.

Risk Factors

Key risks include intense commercial competition from low-cost generic statins and ezetimibe, challenges in securing favorable payer reimbursement, slower-than-expected prescription growth, and the company's ongoing need to manage its cash runway to achieve profitability.

Competitive Landscape

Esperion competes in the lipid management market against generic statins/ezetimibe (cost leaders) and injectable PCSK9 inhibitors/siRNA therapies (efficacy leaders). Its differentiation is its oral, once-daily dosing, muscle-safety profile in statin-intolerant patients, and now proven cardiovascular outcomes benefit, positioning it as a convenient and effective option between generics and injectables.

Publications

Patents

Pipeline

FDA Approvals